UK Pharma Industry Facing Difficult Price Scheme Talks in 2023
Executive Summary
Negotiations on the successor to the UK’s 2019 voluntary drug pricing scheme are due to start in April 2023. The industry body, the ABPI, is calling for a clean sheet approach, but others suggest that could make it almost impossible to reach agreement in less than a year and that reform may be a more realistic proposition.
You may also be interested in...
Two Big Pharma Firms Quit UK Pricing Scheme In Protest Over High Levies
Lilly says the current voluntary drug pricing and access scheme has harmed innovation and left the UK a “global outlier” among major countries, while AbbVie asserts that this year’s repayment rate of 26.5% will impair its ability to operate sustainably in the country. The industry body, the ABPI, says it will come up with proposals for a “completely new settlement” in the coming months.
UK Statutory Scheme Rebate Rise Could Cause Product Shortages & Launch Delays
The pharmaceutical industry is calling on the government to take steps to restore the UK as a location for life sciences investment and recognize the role of competition in the branded generics market, but it will need strong evidence to make the most convincing case.
UK Industry Calls For 'Early & Open' Talks Over ‘Extreme’ 2023 Clawbacks
The current UK approach to drug pricing and access is "broken," and early talks with the government next year will be necessary to set out a "completely new future settlement," the pharmaceutical industry has warned. By contrast, the government claims that the pricing scheme is working as intended.